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Abstract
Background: Parkinson’s disease (PD) is the second most common neurodegenerative disease, presenting with
midbrain dopaminergic neurons degeneration. A number of studies suggest that microglial activation may have a
role in PD. It has emerged that inflammation-derived oxidative stress and cytokine-dependent toxicity may contribute
to nigrostriatal pathway degeneration and exacerbate the progression of the disease in patients with idiopathic PD.
Cell therapies have long been considered a feasible regenerative approach to compensate for the loss of specific cell
populations such as the one that occurs in PD. We recently demonstrated that erythropoietin-releasing neural
precursors cells (Er-NPCs) administered to MPTP-intoxicated animals survive after transplantation in the recipient’s
damaged brain, differentiate, and rescue degenerating striatal dopaminergic neurons. Here, we aimed to investigate
the potential anti-inflammatory actions of Er-NPCs infused in an MPTP experimental model of PD.
Methods: The degeneration of dopaminergic neurons was caused by MPTP administration in C57BL/6 male mice. 2.
5 × 105 GFP-labeled Er-NPCs were administered by stereotaxic injection unilaterally in the left striatum. Functional
recovery was assessed by two independent behavioral tests. Neuroinflammation was investigated measuring the
mRNAs levels of pro-inflammatory and anti-inflammatory cytokines, and immunohistochemistry studies were performed
to evaluate markers of inflammation and the potential rescue of tyrosine hydroxylase (TH) projections in the striatum of
recipient mice.
Results: Er-NPC administration promoted a rapid anti-inflammatory effect that was already evident 24 h after transplant
with a decrease of pro-inflammatory and increase of anti-inflammatory cytokines mRNA expression levels. This effect
was maintained until the end of the observational period, 2 weeks post-transplant. Here, we show that Er-NPCs
transplant reduces macrophage infiltration, directly counteracting the M1-like pro-inflammatory response of
murine-activated microglia, which corresponds to the decrease of CD68 and CD86 markers, and induces M2-like
pro-regeneration traits, as indicated by the increase of CD206 and IL-10 expression. Moreover, we also show that this
activity is mediated by Er-NPCs-derived erythropoietin (EPO) since the co-injection of cells with anti-EPO antibodies
neutralizes the anti-inflammatory effect of the Er-NPCs treatment.
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Conclusion: This study shows the anti-inflammatory actions exerted by Er-NPCs, and we suggest that these cells may
represent good candidates for cellular therapy to counteract neuroinflammation in neurodegenerative disorders.
Keywords: Parkinson’s disease, Erythropoietin, Adult stem cells, Neural stem cells transplantation, Neuroinflammation,
Regenerative medicine
Background
Parkinson’s disease (PD) is characterized by dopamin-
ergic (DA) denervation of the striatum and progressive
death of DA neurons in the substantia nigra pars com-
pacta (SNpc) [1]. Neuroinflammation has a role in sev-
eral neurodegenerative diseases; though it may not be
considered the primary cause, it contributes to the
symptomatic phase [2]. Several lines of research suggest
that neuroinflammation is the major central event in
dopaminergic neural cell death in PD [3–5]. In post-
mortem SN from human PD brains, microglia results
activated, lymphocytes are infiltrated [2, 6], and in cerebro-
spinal fluids, there are high levels of pro-inflammatory cyto-
kines such as tumor necrosis factor (TNF), cyclooxygenase-2
(COX-2), interleukin-1beta (IL-1beta), and IL-18 [7, 8]. It
has been suggested that in CNS neurodegeneration, neur-
onal damage may lead to the activation of microglia and
astrocytes that in turn amplify the inflammatory response
through chemokine secretion. This enhances CNS infiltra-
tion by peripheral immune cells. Studies in the acute
neurotoxic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) mouse model provided evidences that neuroin-
flammatory processes can contribute to nigral DA neur-
onal death [9–11]. Both the genetic deletions of microglial
effectors [12] and the suppression of T lymphocytes [6]
reduced neuronal loss suggesting that neuroinflammation
in PD may actively participate in neuronal death. The
“principal mechanism” that links the inflammatory re-
sponse with neurodegeneration remains to be fully clari-
fied. However, it is recognized that neuronal degeneration
itself and in particular the accumulation and release of
alpha-synuclein aggregates by the injured DA neurons
early in the disease process [13], may act as a signal, and
can activate glial cells to produce and release a variety of
pro-inflammatory molecules, exacerbating microglia acti-
vation and neuronal cell death [14–18]. Within this sce-
nario, the major players are the microglia, the reactive
astrocytes, and the infiltrating monocyte-derived macro-
phages [19]. Upon injury, activated M1-like microglia pro-
liferates and participates in clearing cell debris in the early
stages but may exacerbate brain injury through the pro-
duction of neurotoxic substances, especially when it is
overactivated for prolonged periods [20]. In the M2-like
phenotype, microglia has anti-inflammatory and neuron-
reparative roles, protecting the damaged tissue by remov-
ing cell debris and releasing anti-inflammatory cytokines
needed for tissue repair [21]. Current treatments for PD
are only symptomatic and have no effects on the ongoing
neurodegeneration [22]. The ideal therapeutic treatment
for PD should have both symptomatic and restorative ef-
fects aimed at preserving midbrain DA neurons from de-
generation [23, 24]. In this sense, adult neural stem cells
grafting into animal experimental models of neurodegen-
erative diseases have shown beneficial effects promoting
both trophic and anti-inflammatory actions [25–31].
Recently, we reported the therapeutic potential of
erythropoietin-releasing neural precursors cells (Er-NPCs)
intrastriatally infused in a preclinical model of PD,
obtained upon the administration of MPTP [30, 32]. After
the unilateral transplantation into the striatum of MPTP-
treated C57BL/6 mice, Er-NPCs were vital and capable of
engrafting into the recipient’s brain. Er-NPC-treated ani-
mals improved their typical motor deficits within 3 days of
cell transplantation, and this was accompanied by signifi-
cant sparing of SN neurons. All these features and effects
are likely dependent on erythropoietin’s (EPO) release
since all of these were abolished by the co-injection of
Er-NPCs with anti-EPO (aEPO) or anti-EPO-receptor
(aEPO-R) antibodies. Little is known about the anti-in-
flammatory actions of Er-NPCs transplant in PD brains.
Here, we focus on the study of this aspect and report that
a rapid anti-inflammatory effect was evident 24 h after
Er-NPCs transplant with the decrease of early pro-inflam-
matory cytokines mRNA levels (e.g., IL-1alpha, TNF). This
effect was maintained for the following days, and IL-6
mRNA levels were significantly reduced as far as 7 days
after transplantation. At the end of the 2-week observa-
tional period, histological data confirmed the reduction
of activated microglia marker expression (GFAP and
Iba1) and macrophages infiltration (CD68). Moreover,
at the same time point, we observed the increase of
markers associated with the M2-like protective pheno-
type. Co-injection of Er-NPCs with aEPO antibody neu-
tralizes the Er-NPCs anti-inflammatory activity,
strongly indicating that this effect is mediated by EPO
released from Er-NPCs.
Methods
Animals and study approval
Procedures involving animals and their care were con-
ducted in conformity with the Italian Guidelines for
Laboratory Animals, which conform to the European
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Communities Directive of September 2010 (2010/63/
UE), and the Review Committee of the University of
Milan gave its approval to the study (No 2/2013). Male
C57BL/6 mice (Charles River, Milan, Italy), 12–16 weeks
old and weighing 20–24 g, were kept for at least 7 days
before the experiments and housed in standard condi-
tions (22 ± 2 °C, 65% humidity, and a 12-h light-dark
cycle) with food and water ad libitum. Moreover, in
order to make them amenable, the animals were accus-
tomed to the behavioral tests (horizontal and vertical,
see below for details) daily for 1 week prior to MPTP
injection.
Er-NPCs isolation
Erythropoietin-releasing neural precursors cells (Er-NPCs)
expressing green fluorescent protein (GFP) were isolated 6
h postmortem from adult C57BL/6-Tg(UBC-GFP)30Scha/J
mice weighing 25–30 g (Charles River) as previously de-
scribed [29, 33, 34].
Animal treatments
Experimental animals were divided into five groups: (1)
control (CTRL, healthy animals, n = 24), (2) MPTP-treated
mice (MPTP, n = 24), (3) MPTP-treated mice infused with
PBS (SHAM, sham-operated; n = 18), (4) MPTP-treated
mice transplanted with Er-NPCs (MPTP + Er-NPCs, n =
24), (5) MPTP-treated mice transplanted with Er-NPCs
and anti-erythropoietin antibody (MPTP + Er-NPCs +
aEPO, n = 12). Anti-erythropoietin antibody (sc-7956,
Santa Cruz Biotechnology) was infused at the final
concentration of 3 μg/ml [29, 30, 33, 35]. Parkinsonism
was induced by intraperitoneal (i.p.) administration of
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
in C57BL/6 mice following the acute paradigm with a
small modification. Briefly, animals were administered
a double dose of MPTP hydrochloride: a first i.p. injec-
tion of MPTP (36 mg/kg) and a second i.p. injection of
MPTP (20 mg/kg) after 7 days. Er-NPCs-treated ani-
mals were transplanted with 5 × 104 cells/μl (5 μl) GFP
expressing Er-NPCs, according to the following stereo-
taxic coordinates in relation to bregma: 0.1 mm poster-
ior, 2.4 mm mediolateral, and 3.6 mm dorsal at the
level of left striatum [36]. Please see Table 1 for a de-
tailed number of animals for each group at specific time
points. For gene expression analyses, animals from each
group were sacrificed by cervical dislocation; their brains
were removed and dissected. Immediately after dissection,
the whole striatum, frontal cortex, and midbrain were fro-
zen in dry ice until they were assayed. For immunohisto-
chemistry analyses, animals from each group were
anesthetized by i.p. injection of sodium pentobarbital (65
mg/kg), perfused through the left ventricle with 50mL of
saline solution, and fixed with 200mL of 4% paraformal-
dehyde in 0.1mol/L PBS. The brains were subsequently
removed from the skulls and then cryoprotected at 4 °C in
sucrose 300 g/L and 0.1 mol/L PBS solution for further
sectioning.
Behavioral tests
To investigate the recovery of motor dysfunction after cell
transplantation, two different behavioral tests were per-
formed: horizontal and vertical grid tests [30, 32, 37, 38].
Each animal was tested twice at each time point.
Horizontal grid test
The grid apparatus was constructed according to Tiller-
son and co-workers [30, 32, 37]. The animal was video-
taped for 30 s, and the videos were replayed for
percentage forepaw fault analysis using a recorder with
slow motion option. The number of unsuccessful fore-
paw steps divided by the total number of attempted
forepaw steps was evaluated [37]. The mice were accli-
matized to the grid twice a day for 1 week, before MPTP
treatment. Three observers (ZG, FR, MM) in blind rated
each trial for forepaw faults per step.
Vertical grid test
The vertical grid apparatus was constructed according to
Kim and co-workers [30, 32, 38]. For this test, the mouse
was placed 3 cm from the top of the apparatus, facing
upwards, and was videotaped when turning around and
climbing down. The score reported was the time re-
quired by the mouse to make a turn, climb down, and
reach the bottom of the grid with its forepaw within
180 s [30, 32, 38]. Before MPTP administration, mice
were acclimatized to the grid twice a day for 1 week. The
analysis was performed by three observers in blind (ZG,
FR, MM).
Table 1 Number of animals used for experiments. All animals were tested for behavioral performances
Days post-transplant Analysis CTRL MPTP SHAM MPTP + Er-NPCs MPTP + Er-NPCs + aEPO
1 Real-time RT PCR 6 6 6 6 //
7 Real-time RT PCR 6 6 6 6 //
14 Real-time RT PCR 6 6 6 6 6
Immunohistochemistry 6 6 // 6 6
// = no animals used for this analysis
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Olfactory test
For this test, mice were food deprived for 20 h before the
test. A corn chip was buried under their bedding (1 cm) in
a corner of the cage. Each mouse was positioned at the
center of the testing cage, and the time to retrieve and bite
the corn chip was measured [30]. The analysis was per-
formed by three observers in blind (ZG, FR, MM).
Immunohistochemistry and quantitative analysis
Immunohistochemistry analyses were performed on
20 μm coronal section of the whole brain cut at − 25 °C
using a cryostat (Leica), and slides were collected onto
glass slides and rinsed with PBS and treated with block-
ing solution (10% NGS, 0.2% Triton X-100) following
our previously published protocols [30, 32]. The follow-
ing primary antibodies were used: monocyte/macro-
phages (MOMA/CD68, 1:25; Millipore), CD86 (1:200;
Abcam), mannose receptor (CD206, 1:200; GeneTex),
GFAP (1:1000; Covance), Iba1 (1:250; Abcam), CD11b
(1:200; Abcam), tyrosine hydroxylase (TH, 1:500; Milli-
pore), and DAT (1:200; Millipore). The following sec-
ondary antibodies were used: 546 goat anti-rabbit IgG
(1:200; Alexa), 546 goat anti-mouse IgG (1:200; Alexa),
546 goat anti-rat IgG (1:200, Alexa), and 488 donkey
anti-rabbit IgG (1:200, Alexa). Images were acquired using
standardized confocal microscopy (Leica SP2 confocal
microscope with He/Kr and Ar lasers; Heidelberg,
Germany). Images of striatum immunostaining were ac-
quired in the region corresponding to bregma 2.80/3.52
mm as indicated in the Paxinos and Franklin atlas [39].
Microphotographic digital analysis was performed using
the ImageJ software [30, 32, 40]. The quantification of the
positive pixels versus the negative background elicits an
index score that includes the contributions from fibers
and neuronal somata. The immunostaining conditions
were the same for all sections analyzed; staining solutions
and reaction times were the same. The microscope light
intensity of the laser was the same for the analysis of all
given brain sections and for determining the background
optical density. Co-localization in Fig. 1 was analyzed over
a 3D field obtained by stacking confocal planes acquired
using standardized confocal microscopy (Leica SP (con-
focal microscope); Heidelberg, Germany).
THP1 co-cultures with Er-NPCs
THP1 cells were seeded with fresh RPMI medium supple-
mented with 3% FBS on six trans-well plates at the con-
centration of 5 × 105 cells/well for co-culture experiment
and activated with 50 ng/ml PMA. Twenty-four hours
after seeding, the THP1 was stimulated adding 1 μg/ml
LPS for 1 h. For co-culture experiments, Er-NPCs were
dissociated, counted, and re-suspended in the THP1
Fig. 1 Er-NPCs engraft in the recipient’s brain and differentiate in TH-positive neurons. Confocal images of Er-NPCs intrastriatal distribution (green)
14 days after transplantation in the coronal sections taken from Er-NPCs-injected MPTP mouse brains (bars 50 μm). Co-expression of the cytoplasmic
protein TH (red) and GFP (green) within a cell suggests dopaminergic differentiation of the transplanted Er-NPCs during migration. The histogram
reports the quantification of positive cells to the TH marker in 18 different fields for each condition (n = 6 mice each group; 3 fields for mouse) (see the
“Methods” section). Quantification was done by ImageJ picture analysis. *p < 0.05. Data reported in the histogram are expressed as average ± SD and
refer to three brains for each experimental condition
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medium at the concentration of 4 × 105 cells/well.
Co-culture of THP1 and Er-NPCs with or without aEPO
antibody (5 μg/ml) was performed using 0.4 μm pore
size trans-well inserts (Corning). After 3 h of co-culturing,
inserts were removed and the THP1 were isolated for RNA
extraction and real-time RT-PCR. Dexamethasone was used
(100 μM) as anti-inflammatory positive control [41].
RNA extraction and real-time PCR
Gene expression analyses were performed 7 days after
transplant (n = 6 mice for each group) in striatum ho-
mogenates [29, 33]. The left and right striatum regions
were dissected out rapidly, frozen on dry ice, and stored
at − 80 °C for further analyses. Total RNA was extracted
using TRIZOL® reagent (Life Technologies) following the
manufacturer’s instructions, quantified, and processed as
described [42, 43]. Total RNA (1 μg) was reverse tran-
scribed using iScript cDNA synthesis kit (Bio-Rad) ac-
cording to the manufacturer’s instructions. Real-time
RT-PCR was performed with StepOnePlus™ Real-Time
RT-PCR System (Thermo Fisher) using iQ SYBR Green
Supermix (Bio-Rad). Primers were designed using Oligo
Perfect Designer Software (Life Technologies) and were
checked using the BLASTn tool on NCBI (https://blas-
t.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch),
assessing in silico the specific targeting of the gene. Fur-
thermore, in each RT-PCR reaction, the Tm peak was
analyzed, and only single peak results (indicating specific
amplification of one product) were deemed valid. A
negative control analysis with no cDNA template was
also performed in each RT-PCR to ensure that no con-
tamination was present when performing the reaction.
Primer sequences are reported in Table 2. Amplification
conditions were AmpliTaq activation 95 °C for 10 min,
PCR denaturation step 95 °C for 15 s, PCR annealing
and elongation step 60 °C for 1 min, and 40 cycles of
PCR were performed. Genes were quantified in tripli-
cates, and 18S was used as housekeeping gene. Gene ex-
pression was calculated using the 2−ΔΔCt method.
Statistical analyses
Statistical analyses between groups were evaluated using
GraphPadPrism 4.00 version, and data are expressed as
mean ± SD. Behavioral data were analyzed with a two-way
ANOVA model with time and group (CTRL, MPTP,
SHAM, MPTP + Er-NPCs, and MPTP + Er-NPCs +
aEPO) as factors. The null hypothesis was rejected when
p < 0.05. Gene expression data were analyzed in triplicate
and results were expressed as the average of six animals.
The expression pattern of each gene was analyzed by
one-way ANOVA followed by Bonferroni’s multiple com-
parisons test to assess statistical significance.
Results
Transplanted Er-NPCs integrate into the damaged host
brain and promote a rapid recovery of function
The murine model of Parkinson’s disease was obtained by
the administration of MPTP neurotoxin to C57BL/6 mice,
following the paradigm reported previously [30, 32] (see
the “Methods” section and Additional file 1 for details).
Two weeks post-injection, transplanted Er-NPCs were
engrafted in the recipient’s brain. Figure 1 shows that
transplanted Er-NPCs migrate from the injection site to
different brain sites. Their morphology looks more differ-
entiated presenting a developed soma of good size with
abundant neurite projections in the recipient striatum.
Quantitative co-localization analyses performed in the stri-
atum sections 2 weeks post-injection indicate that 70.01%
(± 5.6) of engrafted Er-NPCs had migrated more than 3.25
mm following a dorso-ventral pathway, supporting previ-
ously reported results [30]. Migration is at least of 2.3mm
from the injection site following a rostro-caudal pathway
(not shown) [30] and a minor percentage of cells (28.58%
± 1.42) even reached the substantia nigra ipsilateral and
contralateral to the injection site [30]. A large portion of
the grafted cells are localized within the striatum, more
than 4–5mm from the injection site, and express markers
of mature neurons, such as Map2 and NeuN, while only a
lower percentage of them was positive to NG2 and Nestin
(82.30 ± 6.88% NeuN; 71.52 ± 9.45% MAP-2, 38.53 ± 5.81%
NG2; 29.71 ± 12.20% Nestin) [30, 32]. TH expression is
present in cells engrafted in the striatum and migrated far
from the injection site (80% of GFP+-Er-NPCs localized
more than 5mm from the injection site) (Fig. 1). The
Table 2 Primer sequences used to study gene expression
m 18S F: AACTTTCGATGGTAGTCGCCGT
R: TCCTTGGATGTGGTAGCCGTTT
m IL1-alpha F: ATGGCCAAAGTTCCTGACTTGTTTGAAGAC
R: GTTGCTTGACGTTGCTGATACTGTCACCCG
m IL1-beta F: GGCAACTGTTCCTGAACTCAACTGTGAAAT
R: CAGGTAGCTGCCACAGCTTCTCCACAGCCA
m IL-6 F: TCCAGTTGCCTTCTTGGGACTGATGCTGGT
R: AGTTTCAGATTGTTTTCTGCAAGTGCATCA
m IL-10 F: CCTGGCTCAGCACTGCTATGCTGCCTGCTC
R: AAGTAACCCTTAAAGTCCTGCATTAAGGAG
m TNF F: GACGTGGAACTGGCAGAAGAGGCACTCCC
R: GAGGCCATTTGGGAACTTCTCATCCCTTTG
h IL1-beta F: ACAGATGAAGTGCTCCTTCCA
R: GTCGGAGATTCGTAGCTGGAT
h TNF F: CACTGAAAGCATGATCCGGGACGTGGAGCT
R: TCTTCCCTCTGGGGGCCGATCACTCCAAAG
h 18S F: GCTTAATTTGACTCAACACGGGA
R: AGCTATCAATCTGTCAATCCTGTC
m mouse, h human
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evaluation of animals’ recovery of function was monitored
with horizontal and vertical grid tests for 2 weeks after
Er-NPCs infusion (2.5 × 105 cells/brain) (Fig. 2) [30, 32].
The administration of the neurotoxin MPTP causes dam-
ages to the nigrostriatal projections. This leads to the in-
crease of forepaw faults of the anterior paw, as it can be
appreciated in the horizontal grid test (Fig. 2a), and
of the time taken to descend from the grid in the
specific test (Fig. 2b). The functional recovery due to
intra-striatal injection of Er-NPCs is already detect-
able in the third day after the transplant as the per-
centage of forepaw faults in mice treated with the
Er-NPCs is 44.55% ± 2.5% compared to 83.02 ± 2.76% of
the MPTP animals group. The initial functional recovery
observed in animals treated with Er-NPCs is maintained for
the entire observational period. In the vertical grid test, the
differences in score between motor features of treated mice
(MPTP + Er-NPCs) and not treated mice (MPTP) are
highly more appreciable (Fig. 2b). The action of Er-NPC
transplantation on the promotion of functional perfor-
mances is also appreciable on the recovery of olfactory cap-
abilities caused by MPTP evaluated by means of olfactory
test (Additional file 2) [30].
Er-NPCs grafts promote the rescue of endogenous
TH-positive projections in the recipient striatum
The protective action of engrafted Er-NPCs was assessed
by investigating the dopaminergic markers in the engrafted
striatum. By performing quantitative confocal laser micros-
copy on striatal sections, we found that Er-NPCs signifi-
cantly counteracted the MPTP-induced loss of both
striatal DAT and TH-positive innervations (Fig. 3). The TH
Fig. 2 Er-NPCs promote functional recovery. Horizontal (a) and vertical (b) grid tests were used for the behavioral analysis, and the percentage of
forepaw faults and the time for descending the grid are shown in the graphs. Five groups of animals were analyzed: (1) control (CTRL, healthy
animals, n = 24), (2) MPTP-treated mice (MPTP, n = 24), (3) MPTP-treated mice infused with PBS (SHAM, sham-operated; n = 18), 4) MPTP-treated
mice transplanted with Er-NPCs (MPTP + Er-NPCs, n = 24), and (5) MPTP-treated mice transplanted with Er-NPCs and anti-erythropoietin antibody
(MPTP + Er-NPCs + aEPO, n = 12). Data are expressed as mean ± SD. Statistical analysis was performed with two-way ANOVA test followed by
Bonferroni post-test. °°°p < 0.001; °°p < 0.01 vs CTRL; ***p < 0.001vs MPTP
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expression was also evaluated in the substantia nigra, and a
concordant pattern was observed (Fig. 3) [30, 32].
Er-NPCs transplantation counteracts pro-inflammatory
cytokines expression in MPTP-recipient mice
MPTP’s administration in models of PD is known to result
in an inflammatory response mediated by an increased ex-
pression of neuro-inflammatory cytokines [2, 9, 44, 45].
We aimed to investigate the expression of neuroinflam-
matory cytokines, quantifying with real-time RT-PCR
the mRNA levels of selected molecules. The MPTP ad-
ministration causes a strong increase in the mRNA
levels of the pro-inflammatory cytokines IL-1alpha and
TNF (Fig. 4). The administration of Er-NPCs counter-
acts this phenomenon reducing these cytokines’ expres-
sion as early as 24 h after cells infusion (Fig. 4). This
effect is significantly evident in the area of the striatum
ipsilateral to the transplant. The expression of other in-
terleukins (IL-6, IL-8, IL-10) and neurotrophic growth
factors (BDNF, NGF) was also evaluated 24 h after
Er-NPCs infusion without observing any significant dif-
ferences between the Er-NPCs-treated group (MPTP +
Er-NPCs) and the not-treated one (MPTP) (data not
shown). The effect of the transplant is further maintained,
as the significant reduction of TNF is still observed 7 days
after the Er-NPCs infusion (Fig. 5a). IL-6, a
pro-inflammatory cytokine, and IL-10, an anti-inflammatory
interleukin, are highly expressed in the late response stage
[45]. Seven days after the injection of Er-NPCs, IL-6 in-
creased by sixfold in MPTP-treated mice compared to the
correspondent cerebral area of control healthy animals
(Fig. 5b). The levels of IL-6 were reduced in the left striatum
Fig. 3 Er-NPCs promote the recovery of DAT and TH immunoreactivity. Confocal images of dopamine transporter (DAT) staining (green) (a) and
tyrosine hydroxylase (TH) (showed in red) (b); of healthy mice (CTRL), mice treated with MPTP (MPTP), and MPTP infused with Er-NPCs (MPTP +
Er-NPCs). Scale bars represent 50 μm. The quantification of fluorescence, represented in the diagram, was performed with the software ImageJ
(NIH). The data reported in the diagram are referred to the mean ± SD (n = 6 mice each group; three fields for mouse). ***p < 0.001; *p < 0.05 vs
CTRL; °°p < 0.01; °p < 0.05 vs MPTP; ###p < 0.001; #p < 0.05 vs MPTP + Er-NPCs
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(ipsilateral to the transplant) of Er-NPCs-infused MPTP
mice, while the action of the transplanted cells was not evi-
dent in the right striatum of recipient mice (contralateral to
the transplant). Conversely, the levels of expression of
anti-inflammatory cytokine IL-10 were significantly in-
creased in MPTP mice treated with Er-NPCs compared to
the MPTP ones both in the left and right striatum (Fig. 5b).
Er-NPCs regulate the expression of neuroinflammatory
markers in the damaged striatum of recipient animals
Different studies demonstrated that stem cells have
anti-inflammatory properties [26, 46], which lead us to
think that the motor recovery we observe in animals
treated with Er-NPCs could be mediated by Er-NPCs’
rapid counteraction of pro-inflammatory cytokines ex-
pression. Furthermore, we wished to clarify whether this
is an effect mediated by EPO released by Er-NPCs dur-
ing the engraftment in the recipient striatum [30, 32].
To dissect the action of Er-NPCs on counteracting neu-
roinflammatory processes, we set up a series of histo-
logical analyses performed at the end of observational
period (2 weeks after Er-NPCs infusion) in which a
group of Er-NPC-treated animals were also co-infused
with anti-erythropoietin antibody. Figure 6a shows that
there are no significant changes in CD11b’s expression, a
well-characterized pan-macrophage and microglia marker
[47, 48], in MPTP mice or after Er-NPCs or Er-NPCs +
aEPO administration. Quantitative data are reported in
the histogram that shows the quantification of fluores-
cence intensity (Fig. 6d) and the number of cells positive
to CD11b marker expression (Additional file 3). To evalu-
ate the presence of activated astrocytes, the levels of glial
fibrillary acidic protein (GFAP) were investigated (Fig. 6b)
[29]. GFAP resulted increased in the striatum slides of
MPTP and MPTP + ErNPCs + aEPO-treated mice, while
it decreased in Er-NPCs-treated mice, both in the ipsilat-
eral and in the contralateral striatum. The expression
levels were quantified for fluorescence intensity and re-
ported in the histogram of Fig. 6d. To investigate the pres-
ence of immune cells, we studied the microglia in the
striatum after the inflammatory stimulus, evaluating the
expression of Iba1 (ionized calcium-binding adapter mol-
ecule 1), a protein codified by the AIF4 gene, which indi-
cates the presence of activated macrophages in inflamed
tissues [49]. Figure 6c shows that in the striatum of MPTP
animals, there is an overexpression of the Iba1 protein. In
Fig. 4 Evaluation of pro-inflammatory cytokines after 24 h (IL-1alpha, TNF). The levels of early cytokines were evaluated with real-time RT-PCR 24 h
after Er-NPCs infusion (IL-1alpha, TNF). The quantification was conducted separately in the both hemispheres (right and left). 18S was used as
housekeeping gene. This study was conducted in triplicate on six different brain samples. The data reported in the histogram are expressed as
mean ± SD. °°°p < 0.001 vs CTRL; ***p < 0.001; **p < 0.01; *p < 0.05 vs MPTP; ###p < 0.001; ##p < 0.01 vs SHAM
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Fig. 5 Evaluation of pro-inflammatory and anti-inflammatory cytokines (IL-1alpha, TNF; IL-6 and IL-10) 7 days after Er-NPCs transplant. The
quantification was conducted by real-time RT-PCR separately in both hemispheres (right and left). 18S was used as a housekeeping gene. This
study was conducted in triplicate on six different brain samples. The data reported in the histogram are expressed as mean ± SD. °°°p < 0.001 vs
CTRL; ***p < 0.001; **p < 0.01; *p < 0.05 vs MPTP; ###p < 0.001; ##p < 0.01 vs SHAM
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the group of MPTP mice transplanted with Er-NPCs, the
presence of Iba1 resulted significantly reduced and com-
parable to the control healthy animals both in the left and
right striatum (Fig. 6c). Furthermore, in the striatal
sections obtained from MPTP animals treated with
Er-NPCs + aEPO, the downregulation of Iba1 expres-
sion was prevented. Indeed, fluorescence’s quantifica-
tion shows that in this case, the signal is comparable
to that of sections obtained from animals belonging
to the MPTP group (Fig. 6d). These data are confirmed
also by the stereological counts of cells positive to the in-
vestigated markers (Additional file 3).
Studies in acute MPTP mouse models provided evidence
of monocyte’s infiltration in the brain [50–52]. To investi-
gate the levels of macrophages infiltration, we evaluated the
expression of CD68, a marker associated with the lysosomal
activity of myeloid cells [48, 53]. CD68 increases after the
administration of MPTP neurotoxin (Fig. 7a), and in the
Fig. 6 Er-NPCs counteract gliosis caused by MPTP. The coronal sections obtained from the brains of mice belonging to the following
experimental groups (CTRL, MPTP, MPTP + Er-NPCs ipsilateral and contralateral, MPTP + Er-NPCs + aEPO ipsilateral) were labeled with the antibody
CD11b (a), GFAP (b), and Iba1 (c) in red. Scale bars represent 50 μm (CD11b and GFAP) and 20 μm (Iba1). Quantification was done by ImageJ picture
analysis software and reports the fluorescence intensity/pixel expressed by the studied markers in 18 different fields for each condition (n = 6 mice
each group; 3 fields for mouse) (see the “Methods” section). ***p < 0.001; **p < 0.01; *p < 0.05 vs CTRL; ###p < 0.001; ##p < 0.01; #p < 0.05 vs MPTP; °°°p <
0.001 vs MPTP + Er-NPCs ipsilateral; §§§p < 0.001vs MPTP + Er-NPCs contralateral
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ipsilateral and contralateral sections of the striatum trans-
planted with Er-NPCs, its immunoreactivity is significantly
decreased. The histograms shown in panel d of the same
figure report the quantification of fluorescence
(Fig. 7d). The microglia has two different activation
phenotypes, defined as M1-like (with a pro-inflamma-
tory action) and M2-like (with an anti-inflammatory ac-
tion) [54]. These two phenotypes develop different actions
depending on their released mediators. The M1-like
phenotype releases pro-inflammatory cytokines and other
pro-inflammatory molecules such as NO and ROS. On
the contrary, M2-like microglia release anti-inflammatory
cytokines [20]. To discriminate between the two macro-
phages subtypes that infiltrate the degenerated striatum
(M1 vs M2), we studied the immunoreactivity to
phenotype-specific markers. In particular, we investigated
Fig. 7 Er-NPCs engraftment counteracts macrophages invasion and allows the switch from M1 to M2 subtype. Immunohistochemistry analysis of
coronal sections obtained from the brain of healthy control animals, treated with MPTP and with MPTP + Er-NPCs ipsilateral and contralateral to
the transplant site and with MPTP + Er-NPCs + aEPO ipsilateral to the transplant site. The brain sections were labeled with the antibody CD68 (a),
CD86 (b), and CD206 (c) in red. Scale bars represent 50 μm (CD68, CD86, and CD 206). Quantification was done by ImageJ picture analysis software and
reports the fluorescence intensity/pixel expressed by the studied markers (n= 6 mice each group; three fields for mouse) (see the “Methods” section).
***p< 0.001; **p< 0.01 vs CTRL; ###p< 0.001; ##p < 0.01; #p < 0.05 vs MPTP; °°°p < 0.001; °°p< 0.01; °p < 0.05 vs MPTP + Er-NPCs ipsilateral; §§§p< 0.001;
§§p < 0.01 vs MPTP + Er-NPCs contralateral (d)
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the expression of CD86, marker of macrophages M1-like
(Fig. 7b) and of CD206, a mannose receptor, and a typical
marker of M2-like macrophages (Fig. 7c) [20]. The expres-
sion of CD86 was significantly increased in MPTP mice,
while in mice treated with Er-NPCs, the levels of CD86
decreased, both in the ipsi and in the contralateral sites to
the transplant (Fig. 7b). In MPTP mice co-administrated
with Er-NPCs and aEPO antibody, the reduction of CD86
mediated by the cells was inhibited. An opposite pattern
was observed for the CD206 marker, with a very low ex-
pression of this marker in MPTP mice and MPTP mice
treated with Er-NPCs + aEPO (Fig. 7c). CD206 resulted in
a high increase in MPTP mice treated with Er-NPCs
(Fig. 7c). The quantification of fluorescence intensity rela-
tive to the expression of each marker is reported in Fig. 7d.
Moreover, these observations are confirmed also by the
stereological counts of cells positive to the investigated
markers (Additional file 4).
The anti-inflammatory effect of Er-NPCs is mediated by EPO
To confirm that the anti-inflammatory actions exerted by
the Er-NPCs transplanted were connected to the release of
EPO, at the end of the observational period (2 weeks after
transplantation) six brains for each experimental group
were explanted without perfusion. The striatum and sub-
stantia nigra were dissected from each brain, total RNA
was extracted, and the RNA expression of pro-inflamma-
tory cytokines IL-6 and TNF was evaluated (Fig. 8). The
results of the expression analysis show that Er-NPCs trans-
plant significantly allows the reduction of pro-inflammatory
cytokines in both the striatum and substantia nigra of re-
cipient animals (Fig. 8). The co-administration of Er-NPCs
with aEPO antibody inhibits the therapeutic effect of trans-
planted cells. Indeed, in these animals and in the MPTP
non-transplanted animals, the levels of all the studied cyto-
kines resulted in significant increase as opposed to control.
This observation is in complete concordance with what
has been observed by immunofluorescence analysis of
neuro-inflammatory markers.
Er-NPCs override the pro-inflammatory cytokine
production by macrophages in vitro
To further investigate whether the anti-inflammatory
properties were due to the transplanted neural precursors,
Fig. 8 The co-administration of aEPO with Er-NPCs abrogated their positive effect on pro-inflammatory cytokines. At 2 weeks after transplantation,
mRNA levels of IL-6 and TNF were quantified in the striatum (a) and substantia nigra (b). 18S was used as a housekeeping gene. The evaluation
was performed in triplicate on six different brain samples. The data reported in the histogram are expressed as mean ± SD. ***p < 0.001 vs CTRL;
###p < 0.001 vs MPTP; $$$p < 0.001 vs SHAM; °°°p < 0.001 vs MPTP + Er-NPCs
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we performed an expression analysis of pro-inflammatory
cytokines IL1-beta and TNF using an in vitro system that
recapitulates the inflammatory microenvironment. THP1
cells were differentiated with PMA for 24 h (100 μM) and
activated using LPS for 1 h (1 μg/ml) [55] (please see sche-
matic representation in Fig. 9). Then, Er-NPCs were added
using a trans-well approach and maintained in the
co-culture trans-well system for 3 h. As expected, the
THP1 macrophages showed a significant increase in the
expression levels of TNF and IL1-beta mRNAs. The pres-
ence of Er-NPCs counteracted the expression of both
pro-inflammatory cytokines with respect to THP1 macro-
phages (Fig. 9). The co-incubation with Er-NPCs in pres-
ence of anti-EPO antibody (5 μg/ml) partially inhibited the
effect exerted by Er-NPCs (Fig. 9).
Discussion
Many reports have shown the ability of transplanted
neural stem cells to modify the environment of the re-
cipient tissue and give rise to positive effects in animal
experimental models of PD. Here, we uncover the
anti-inflammatory action exerted by engrafted Er-NPCs
in an MPTP model of PD. Their transplantation
promoted functional recovery and resulted in the sparing
of dopaminergic nigro-striatal projections. By perceiving
signals coming from the microenvironment of damaged
tissue, stem cells can migrate to specific sites in the body
and respond to a specific signal by releasing cytokines and
modifying their own fate [56]. All of these features allow
stem cells to be a possible therapeutic approach for many
neurodegenerative diseases, including PD.
Here, we used accessible, stably expandable, and
well-characterized erythropoietin-releasing neural pre-
cursors cells (Er-NPCs) [29–34]. The aim of this work
was to investigate the mechanisms exerted by Er-NPCs
transplantation in a mouse model of PD, obtained with
MPTP administration, which mimics the inflammatory
process related to the pathology [50–52, 57].
Transplanted Er-NPCs survived after transplantation,
differentiated in the recipient striatum, and induced signifi-
cant amelioration in functional motor symptoms caused by
MPTP intoxication 3 days post-transplantation, as well as
reduced pro-inflammatory cytokines 24 h after the infusion.
These results support the hypothesis that the transplanted
Er-NPCs inhibit the neuroinflammatory phenomena associ-
ated with Parkinsonism induced by the administration of
Fig. 9 Er-NPCs inhibit the expression of pro-inflammatory cytokines in co-culture experiment. a Schematic of experimental set up for in vitro
THP1 cells activation to macrophages and co-cultures with Er-NPCs. The assay was performed in trans-well. b mRNA expression levels of pro-
inflammatory cytokines IL-1beta and TNF in co-culture experiments. mRNA levels were evaluated by real-time RT-PCR in not-treated activated
THP1 versus co-culture with Er-NPCs, Er-NPCs + aEPO, and activated THP1 treated with dexamethasone (100 μM) a potent anti-inflammatory and
immunosuppressive agent used as control. The co-culture assay lasted for 3 h. The experiment was repeated trice, and each point was assayed in
triplicate. The data reported in the histogram are expressed as mean ± SD. ***p < 0.001 vs THP1 + LPS; ###p < 0.001 vs Er-NPCs/THP1 + LPS; °°°p < 0.001;
°p < 0.05 vs Er-NPCs + aEPO/THP1 + LPS
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MPTP neurotoxin, via an EPO-dependent mechanism.
Moreover, although the expression of specific markers of
macrophages polarization is not completely categorized
[58], the transplanted neural precursors interact with the
recipient microenvironment and stimulate tissue response
to inflammation, supporting the transition of macrophages
from M1-like phenotype to M2-like, towards a more pro-
tective action [59]. It would require specific assays such as
RNASq experiments to dissect deeply the macrophages
pathways involved. We have observed that there is no dir-
ect contact between M2-like macrophages (positive to
CD206) and transplanted Er-NPCs, suggesting that the ob-
served transition does not require the direct contact with
the cells but can probably be ascribed to a paracrine
phenomenon. The mechanism could be related to a local
counteraction of inflammation and neuroprotective action
mediated by EPO [30, 32, 59–61] on neurons and neural
processes affected by MPTP. Neuroinflammation is a
physiologic response to the administration of the MPTP
toxin resulting in microglia activation which secretes
multi-functional immunoregulatory factors, most notably
TNF, IL-1 and IL-6 families, interferon gamma (IFN--
gamma), and transforming growth factor beta (TGF-beta),
[62, 63]. All of these factors act in context-dependent ways
to modulate inflammatory processes and the permeability
of the BBB [15, 64, 65]. Anti-inflammatory properties of
Er-NPCs are shown by the fact that their transplant down-
regulates IL-6 and TNF mRNA levels and reduces macro-
phages invasion in the striatum and in the SNpc of
recipient mice.
This is consistent with our previous work performed
in experimental traumatic spinal cord injury, which re-
ported the reduction of inflammatory cytokine levels
and macrophage infiltration after the treatment with
rhEPO [60] or administration of Er-NPCs [29, 33]. This
seems to happen also in the present work, as there is a
counter-action of the inflammatory events caused by
MPTP, particularly ipsilateral to the injection site. More-
over, we observed here that transplanted Er-NPCs were
able to counteract the expression of activated microglia’s
markers both in the ipsi- and contra-lateral striatum.
This further validates our previous evidences [30, 32]
showing that the inhibition of EPO’s release by Er-NPCs
influenced the striatum microenvironment by reducing
endogenous EPO expression [32]. Thus, we could specu-
late that the action on contralateral neuroinflammation
can be ascribed both to the diffusion of EPO released by
engrafted precursors and by the modification of the local
microenvironment [32]. The counteractive effects on as-
trocytes (GFAP staining reduction) are quite relevant
since this type of cells are highly activated in PD and
produce an elevated level of inflammatory cytokines and
reactive oxygen species [66]. Moreover, such an activa-
tion is correlated with increased neuronal death [67, 68].
We found that the levels of pro-inflammatory cyto-
kines, such as IL-1alpha, TNF, and IL-6 mRNA levels,
are significantly reduced 24 h (IL1-alpha, TNF) and 1
week (IL-6) after Er-NPCs administration in contrast
with IL-10, an anti-inflammatory cytokine, which re-
sulted increased in the ipsilateral striatum 1 week after
administration of Er-NPCs. The variation in the mRNA
levels of cytokines is concordant with the decrease of
CD86 (marker of macrophage phenotypes M1-like) and
the increase of the level of CD 206 (marker of macro-
phages M2-like). Moreover, our results suggest that EPO
released by Er-NPCs is implicated in the shift from a
pro-inflammatory to a positive phagocytic state [58, 59,
69]. Phenotypic M changes are associated with no major
changes in overall CD11b immunoreactivity in
MPTP-treated animals transplanted with Er-NPCs with
respect to CTRL. This could be explained by the fact
that both resident microglia and infiltrated macrophages
are positive to CD11b staining following central nervous
system injuries [47, 48]. It has been shown that both pheno-
types have phagocytic functions: under pro-inflammatory
conditions M1-like macrophages, being toxic cells, target
viable neurons, cause their death, and help in the propaga-
tion of the damage. On the other hand, under anti-inflam-
matory stimuli, M2-like subtype macrophages, being
protective, with their phagocytic activity remove toxic cellu-
lar debris and dying cells to allow the creation a favorable
microenvironment for the recovery [70, 71]. The ability of
Er-NPCs to influence and limit the “pro-inflammatory
activity” might be a key pathway to confer protection
from PD.
This work confirmed that after the infusion, most of
Er-NPCs survive (≥ 75%) [32] in the striatum and differ-
entiate mainly in neurons [32]. The engrafted precursors
migrate in the distal zones from the injection site and
show a higher capacity to differentiate: 60% of these cells
are positive to MAP2, and more than 80% express the
NeuN marker.
This data, if considered together with the results ob-
tained from the transplant of Er-NPCs in traumatic
spinal cord injury model [29, 30], shows that these
neural precursors are able to interact with the micro-
environment where they are infused and differentiate to
specific lineages [29, 32].
One of the most encouraging results of the pre-clinic
approach that characterizes this work is the study of
functional recovery in animals treated with Er-NPCs. In-
deed, the motor recovery is already evident at the third
day after transplant; it is further improved during the
full observational period of 2 weeks, and it is maintained
up to 2 months after the transplant [30]. The positive re-
sults obtained from the analysis of the motor capabilities
are supported by observations obtained via immunohis-
tochemistry analysis that demonstrate that precursor’s
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transplantation promotes the recovery of TH projections
and DAT expression in the recipient striatum associated
with the recovery of TH-positive cellular bodies in the
SNpc [30]. Aiming to characterize the mechanism of ac-
tion of injected Er-NPCs, we have studied the role of
EPO when released by Er-NPCs [34] in vivo and in vitro.
The inhibition of EPO’s action, caused by the co-admin-
istration of the aEPO antibody both in the in vivo and in
the in vitro macrophage activation assay, allowed us to
validate that the release of this cytokine by the Er-NPCs
is one of the mechanisms responsible for their capability
to counteract neuroinflammation. EPO’s neuroprotective
and anti-inflammatory effects are very well studied and
widely supported in the literature [72]. EPO analogs or
non-erythropoietic-mutant EPO variants showed neuropro-
tective actions in MPTP-induced neurotoxicity and had
neuro-rescue effects in rodent models of PD [73–76]. Inter-
estingly, the administration of aEPO antibody in the in vitro
macrophages activation assay only partially suppresses the
effect of Er-NPCs on TNF mRNA expression levels. This
suggests that the feature of Er-NPCs to act as biological
disease-modifying agents should not only be due to EPO
but possibly to other unknown anti-inflammatory mole-
cules released by these cells.
Conclusion
In conclusion, the data presented in this work suggests
that the adult neural precursors releasing EPO represent
an interesting model of stem cell therapy approach.
Er-NPCs are able to interact with and improve the micro-
environment of the damaged tissue thanks to the release
of protective factors such as EPO. Moreover, our data sug-
gests that erythropoietin can be a potential pharmaco-
logical therapy useful for the treatment of Parkinson’s
disease, thanks to its anti-inflammatory properties.
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Additional file 1: Experimental plan. (PDF 214 kb)
Additional file 2: Er-NPC-treated animals recover olfactory capabilities.
Five groups of animals were analyzed with this test: 1) Control (CTRL,
healthy animals, n = 24); 2) MPTP treated mice (MPTP, n = 24); 3) MPTP
treated mice infused with PBS (SHAM, sham operated; n = 18); 4) MPTP
treated mice transplanted with Er-NPCs (MPTP + Er-NPCs, n = 24) 5) MPTP
treated mice transplanted with Er-NPCs and anti-erythropoietin antibody
(MPTP + Er-NPCs + aEPO, n = 12). Data are expressed as mean ± SD.
Statistical analysis was performed with two-way ANOVA test followed by
Bonferroni post-test. °p < 0.05 vs CTRL; ***p < 0.001 vs MPTP. (PDF 197 kb)
Additional file 3: Percentage of cells positive to CD11b, GFAP, and Iba1.
Graphs report the stereologic counts of positive cells to investigated
markers quantified in nine different fields for each condition (three mice
for each group). The analysis was performed 2 weeks after Er-NPCs
injection. Quantification was done by ImageJ picture analysis software. Data
are expressed as mean ± SD. ***p < 0.001; **p < 0.01 vs CTRL; ###p < 0.001;
##p < 0.01 vs MPTP; °°°p < 0.001; °p < 0.05 vs MPTP + Er-NPCs ipsilateral;
§§§p < 0.001 vs MPTP + Er-NPCs contralateral. (PDF 185 kb)
Additional file 4: Percentage of cells positive to CD68, CD86, and
CD206. Graphs report the stereological counts of positive cells to
the investigated markers quantified in nine different fields for each
condition (three mice for each group). The analyses were performed by
evaluating nine different fields for each condition (three mice for each
group). Quantification was done by ImageJ picture analysis software.
Data are expressed as mean ± SD. ***p < 0.001; **p < 0.01; *p < 0.05 vs
CTRL; ###p < 0.001; #p < 0.05 vs MPTP; °°°p < 0.001 vs MPTP + Er-NPCs
ipsilateral; §§§p < 0.001; §p < 0.05 vs MPTP + Er-NPCs contralateral.
(PDF 181 kb)
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